Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | UQCRB | P14927 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658363 | 0.91 | BRD4 (0.49) | RORCBRD4AURKAKDRAURKB | |
| SCHEMBL8274370 | 0.89 | NR3C2 (0.57) | RORCBRD4NR3C2SMN1; SMN2IKBKB | |
| SCHEMBL22928261 | 0.80 | CYP3A4 (0.48) | RORCNR3C2IKBKBLRRK2UQCRB | |
| SCHEMBL10192115 | 0.79 | SMN1; SMN2 (0.55) | BRD4TP53AURKAKDRAURKB | |
| SCHEMBL4403147 | 0.78 | NR3C2 (0.54) | BRD4NR3C2SMN1; SMN2IKBKBUQCRB | |
| SCHEMBL13935835 | 0.78 | UQCRB (0.49) | RORCIKBKBUQCRBCA1CA2 | |
| SCHEMBL22928007 | 0.78 | EPHA3 (0.43) | RORCNR3C2SMN1; SMN2IKBKBUQCRB | |
| SCHEMBL16868361 | 0.78 | BRD4 (0.49) | BRD4TP53AURKAKDRAURKB | |
| SCHEMBL28216263 | 0.78 | HSD17B2 (0.51) | BRD4TP53AURKAKDRAURKB | |
| SCHEMBL20098109 | 0.78 | KIT (0.50) | BRD4TP53AURKAKDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | RORC 1009/4885BRD4 5/4885TP53 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.